Pfizer Ventures
Investor profile
Venture capital
Also recorded as: Pfizer · Pfizer Venture Investments
Deals
23
distinct rounds
Companies
17
backed
Active span
2016–2026
11 yrs
Total round €
€887M
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- M Ventures7
- Andera Partners3
- BioMedPartners3
- British Patient Capital3
- GIMV3
- IP Group PLC3
- Novartis Venture Fund3
- Oxford Science Enterprises3
- Bpifrance2
- Cambridge Innovation Capital2
- Canaan Partners2
- Earlybird Venture Capital2
- EQT Life Sciences2
- Mission BioCapital2
- Omega Funds2
- Pontifax Funds2
- Sofinnova Partners2
- Taiho Ventures2
- UTokyo Innovation Platform2
- Abingworth LLP1
- Arkin Holdings1
- Avidity Partners1
- Balaji Srinivasan1
- Boehringer Ingelheim Venture Fund1
- Cambridge Enterprise1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Anaveon | Switzerland | 1 | €106M |
| Imcheck Therapeutics | France | 2 | €100M |
| Artios | UK | 1 | €99M |
| Immunos Therapeutics | Switzerland | 3 | €91M |
| Grey Wolf Therapeutics | UK | 2 | €88M |
| Storm Therapeutics | UK | 2 | €76M |
| Anjarium Biosciences | Switzerland | 1 | €51M |
| Vivet Therapeutics | France | 1 | €45M |
| FoRx Therapeutics | Switzerland | 1 | €43M |
| Agomab Therapeutics | Belgium | 1 | €41M |
| Nucleome Therapeutics | UK | 1 | €38M |
| Enara Bio | UK | 1 | €29M |
| Trimtech Therapeutics | UK | 1 | €29M |
| MISSION Therapeutics | UK | 2 | €25M |
| Metabomed | Israel | 1 | €16M |
| Amra | Sweden | 1 | €8.2M |
| VitaDAO | Germany | 1 | €3.8M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Anaveon | Series B | €106M | 2021-12 |
| Artios | Series D+ | €99M | 2025-11 |
| Immunos Therapeutics | Series B | €68M | 2022-06 |
| Imcheck Therapeutics | Other | €54M | 2020-09 |
| Anjarium Biosciences | Series A | €51M | 2021-09 |
| Storm Therapeutics | Series C | €48M | 2026-04 |
| Imcheck Therapeutics | Series B | €46M | 2019-09 |
| Grey Wolf Therapeutics | Series B | €45M | 2023-01 |
| Vivet Therapeutics | Other | €45M | 2018-12 |
| FoRx Therapeutics | Series A | €43M | 2025-12 |